Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|12/02/2019||Change of Director's Interest Notice-Mr Chris Ntoumenopoulos||Download|
|12/02/2019||Change of Director's Interest Notice-Dr William Garner||Download|
|12/02/2019||Change of Director's Interest Notice-Mr Peter Molloy||Download|
|31/01/2019||Race Receives $228k R&D Tax Incentive Refund||Download|
|25/01/2019||Appendix 4C - quarterly||Download|
|22/01/2019||Race appoints leading haematologist to support Bisantrene||Download|
|07/01/2019||Change of Director's Interest Notice-Dr William Garner||Download|